首页> CPT: pharmacometrics & systems pharmacology> Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

导出 LinkOut

翻译打印收藏纠错

第一作者： Stefan,Willmann

第一单位： Bayer AG, Research & Development, Pharmaceuticals, Wuppertal/Leverkusen, Germany.

作者： Stefan,Willmann ^[1] ; Ibrahim,Ince ^[1] ; Maurice,Ahsman ^[2] ; Katrin,Coboeken ^[1] ; Yang,Zhang ^[1] ; Kirstin,Thelen ^[1] ; Dagmar,Kubitza ^[1] ; Peter,Zannikos ^[3] ; Wangda,Zhou ^[3] ; Liza Miriam,Pina ^[3] ; Teun,Post ^[2] ; Jörg,Lippert ^[1]

作者单位： Bayer AG, Research & Development, Pharmaceuticals, Wuppertal/Leverkusen, Germany. ^[1] Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands. ^[2] Janssen Research & Development, LLC, Raritan, New Jersey, USA. ^[3]

医学主题词青少年(Adolescent);成年人(Adult);抗凝药(Anticoagulants);体重(Body Weight);儿童(Child);儿童, 学龄前(Child, Preschool);心脏缺损, 先天性(Heart Defects, Congenital);人类(Humans);婴儿(Infant);婴儿, 新生(Infant, Newborn);静脉血栓栓塞(Venous Thromboembolism)

DOI 10.1002/psp4.12830

PMID 35665486

发布时间 2022-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

CPT: pharmacometrics & systems pharmacology

CPT

2022年11卷8期

1111-1121页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

CPT

2022年11卷8期

1111-1121页

检索历史清除

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

CPT

相似文献

同项目论文

CPT

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

CPT

相似文献

同项目论文

CPT

相关期刊

检索历史清除